The 2-year- phase 1/2 APOLLO study included 75 patients treated with Bimatoprost SR 6 µg, 10 µg, 15 µg, or 20 µg in the study eye and topical bimatoprost 0.3% once daily in the fellow eye.

Disclosures November 07, 2017 0 Efficacy and Safety of Bimatoprost in Glaucoma and Ocular Hypertension in Nonresponder Patients Brennan N, Dehabadi MH, Nair S, et al Int J Ophthalmol. 2017;10:1251 ...

Allergan then filed a resubmission, requesting that LUMIGAN RC 0.01% be reviewed as a new chemical entity rather than as a therapeutic alternative to any other product containing bimatoprost.

Some patients treated with a bimatoprost slow-release implant over 1 year can maintain the IOP-lowering effect without relapse for 2 years or even 4 years after the last administration, according ...

Four doses of the bimatoprost SR implant (6, 10, 15, or 20 µg) were studied; the fellow eye was treated with topical bimatoprost 0.03% once daily.

You use a special applicator to draw bimatoprost along your upper eyelash line. This way, only a small amount gets close to your eye, which lowers the chance of a bad reaction. Some people still ...

Caption This silicone ring loaded with the glaucoma drug bimatoprost sits on the surface of the eye underneath the eyelids. The first clinical trial results showed that the sustained-release ...

SpyGlass Pharma has reported early human data on its drug-eluting intraocular lens. The first-in-human clinical trial linked the bimatoprost delivery devices to a 45% reduction in intraocular ...